Ocugen Inc. (OCGN): Price and Financial Metrics
OCGN Price/Volume Stats
| Current price | $0.92 | 52-week high | $2.11 |
| Prev. close | $0.87 | 52-week low | $0.36 |
| Day low | $0.85 | Volume | 4,374,700 |
| Day high | $0.94 | Avg. volume | 6,101,745 |
| 50-day MA | $0.99 | Dividend yield | N/A |
| 200-day MA | $1.29 | Market Cap | 267.58M |
OCGN Stock Price Chart Interactive Chart >
Ocugen Inc. (OCGN) Company Bio
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
OCGN Price Returns
| 1-mo | -1.08% |
| 3-mo | -29.23% |
| 6-mo | -47.43% |
| 1-year | 136.69% |
| 3-year | -87.86% |
| 5-year | 225.66% |
| YTD | 60.00% |
| 2023 | -55.77% |
| 2022 | -71.43% |
| 2021 | 148.63% |
| 2020 | 251.92% |
| 2019 | -90.37% |
Loading social stream, please wait...